Related Experiment Video
Updated: Mar 3, 2026
Application of Microwave Ablation in Laparoscopic Partial Splenectomy
Published on: November 15, 2024
[Progress on Treatment of Splenic Marginal Zone Lymphoma-Review]
Ling Wu1, Chen Tian2, Yi-Zhuo Zhang1
1Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Thearpy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China.
Abstract:
Splenic marginal zone lymphoma (SMZL) is an uncommon indolent B-cell non-Hodgkin's lymphoma. The clinical features of SMZL are splenomegaly, lymphocytosis and cytopenia in peripheral blood. Immunopheno-typically, the neoplastic cells are typically positive for CD45, CD20, CD79a, PAX5, IgD, BCL-2. The previous common used treatment is splenectomy and chemotherapy. Nowadays, rituximab-based chemotherapy regimens has improved the curative effect dramaticlly. IFN-α with or without ribavirin can be used to treat the patients with HCV infection. Some new target agents such as Bruton tyrosine kinase, NOTCH inhibitor, CAL-101 are under clinical research. This review mainly discuss the progress in the treatment of SMZL.
